The present invention encompasses structures of the formula (I) and the pharmaceutically acceptable non-toxic salts thereof wherein T is halogen, hydrogen, hydroxyl, amino or straight or branched chain lower alkoxy having 1-6 carbon atoms; X is hydrogen, hydroxyl or straight or branched chain lower alkyl having 1-6 carbon atoms; W is phenyl substituted with a 3,4-methylenedioxy, 3,4-ethylen...

PCT No. PCT/DK94/00407 Sec. 371 Date Nov. 27, 1996 Sec. 102(e) Date Nov. 27, 1996 PCT Filed Oct. 28, 1994 PCT Pub. No. WO95/12591 PCT Pub. Date May 11, 1995The present invention relates to phenylindole compounds of formula I: (I) related to atypical neuroleptic sertindole.

The invention relates to a method of administering a liposome preparation having an effective amount of an electrically charged component which is effective in reducing adverse effects of a liposome preparation, e.g., in reducing hemodynamic effects, and improving host tolerance.

The present invention provides novel compositions, unexpectedly advantageous for controlling nematode, insect or acarid infestation of a plant, comprising a quantitatively variable combination of a compound of formula (I) in combination with selected adjuvants from among the typical wetting, dispersing or emulsifying agents, preferably, for example Tergitol3.

This application relates to an aqueous formulation of fenbendazole which is stable and efficacious, does not agglomerate upon standing and wherein the fenbendazole remains in suspension after standing for twenty-four hours.

A process is disclosed for preparing long-acting alpha interferon-containing compositions. Alpha interferon is contacted with a relatively small molar excess of a substantially non-antigenic polymer in the presence of a surfactant to preserve bioactivity. Isolation of the desired conjugate species having optimal activity is also disclosed.

PCT No. PCT/EP94/04055 Sec. 371 Date Jun. 6, 1996 Sec. 102(e) Date Jun. 6, 1996 PCT Filed Dec. 6, 1994 PCT Pub. No. WO95/16007 PCT Pub. Date Jun. 15, 1995The invention relates to chiral compounds containing at least one divalent or polyvalent chiral group, at least one polymerizable group, at least one spacer and at least one mesogenic group, and to their use as polymerizable, chiral dopes for the...

In accordance with the present invention, there is provided a novel composition of matter having formula (I) wherein Ra, Rb, Rc, Rd and Re are independently selected from the group consisting of H, alkyl groups and substituted alkyl groups having about 1 to 10<6> carbon atoms, alkenyl groups and substituted alkenyl groups having about 3 to 10<6> carbon atoms, wherein the substituents on the alkyl ...

The present invention relates to compounds of formula (1), including all of its stereoisomers, compositions, and processes for preparation of the same. The compounds of the present invention are also useful in their pharmacological activities as they directly act as inhibitors of prolyl endopeptidase and thereby provide a method for memory enhancement, preventing or slowing the affects of amnesia ...

A method for preventing or reducing restenosis wherein a 27-hydroxycholesterol or a 25,26 and/or 27-aminocholesterol, or a sterol 27-hydroxylase stimulant, is administered in a restenosis preventing and/or reducing amount.

Mucosal adhesive devices are provided for use in the oral cavity for therapy against infections. The devices are dosage units which comprise a combination of antimicrobial agents such as antifungal agents and anti-inflammatory agents, optionally also a local anesthetic. The dosage units yield a gradual and relatively constant release of the pharmaceuticals over at least a 12-hour period.

Described are preferred processes for preparing 2-halo-5-substituted pyridine compounds. Preferred processes can be conducted in a one-step, one-pot fashion, and involve the reaction of a formamide and a halogenating agent with a nitrile such as cis-2-pentenonitrile or with a combination of reactants including an aldehyde such as n-propionaldehyde and a nitrile or an amide. Preferred processes pro...

This invention relates to naphthalene dicarboxylic acids or naphthalene dicarboxylic esters substituted with aroyl groups. More particularly, this invention relates to the following compounds: dialkyl 1-benzoyl-2,6-naphthalene dicarboxylate, 7-C1-C8-alkoxycarbonyl-1-C1-Cs-alkoxy-l-aryl(1,3-H2 naphtho {1,2-c} furan-3-ones), and dialkyl 1-(2-naphthoyl)-2,6-naphthalene dicarboxylate. The compounds ar...

An improved process for the preparation of 3-chlorobenzo[b]thiophene-2-carbonyl chlorides is described where a cinnamic acid is converted in the presence of thionyl chloride and a 4-N,N'-disubstituted aminopyridine in one step to the desired product.

An anhydrous denture cleansing composition is disclosed comprising anhydrous perborate, a perborate monohydrate, a lubricant and compression aid, a monopersulfate, one or proteolytic enzymes, a sequestering agent, and, optionally, excipients, builders, colors, flavors, and surfactants.

Pharmaceutical compositions for aerosol delivery comprising a medicament, a non-chlorofluorocarbon propellant and a protective colloid, as well as a method for preparing such compositions in which the aggregation of the particles is prevented without the use of surfactants or cosolvents.

Gas and gaseous precursor filled microspheres (1), and foams thereof, provide novel topical and subcutaneous delivery vehicles for various active ingredients, including drugs and cosmetics (2).

Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.

2-spiro (2'-spirocycloalkyl) cyclopropyl cephalosporin sulfone compounds, methods of treating patients for elastase inhibition, and processes for preparing such compounds.

PCT No. PCT/EP94/03948 Sec. 371 Date Jun. 7, 1996 Sec. 102(e) Date Jun. 7, 1996 PCT Filed Nov. 28, 1994 PCT Pub. No. WO95/15954 PCT Pub. Date Jun. 15, 1995A compound of formula (I) or a salt thereof: membered heterocyclic ring selected from the group consisting of thienyl, furyl, pyrrolyl, triazolyl, diazolyl, tetrazolyl, imidazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, py...